Browse all Canadian datasets
Browse the complete CanQuery catalogue, including downloadable files, live tables and maps.
Open datasets
- By-Law Z-222.13
- Double-bunking in Canadian Federal Corrections 2018-19 to 2022-23
- Criminal Risk Index Validation for Indigenous and Non-Indigenous Men
- Fire - Public Events
- HSR Bus Distance Travelled Between Preventable Collisions
- SIU Authorizations: April 1st to September 30th, 2022 (Quarterly Report Q1 & Q2)
- Non-Fatal Overdose Incidents in Federal Custody - 2020-2021
- Trust Statistical Tables (2017 to 2021 tax years)
- Trust Statistical Tables (2016 to 2020 tax years)
- Trust Statistical Tables (2015 to 2019 tax years)
- Employee Remuneration 75k
- Elected Officials Remuneration
- Building Permits
- Ward Profiles, 2018 (47-Ward Model)
- Ward Profiles, 2014-2018 Wards (44-Ward Model)
- Parking Meter Rate Zones
- City Infrastructure 2023
- Business Licences Issued Past 10 Years (2014-2023)
- By-Law Z-222.23 Cash in Lieu Parking Policy
- By-Law Z-222.21 and schedule
- By-Law Z-222.20 and schedule
- 2023 OIC Progress Report, Accessible Canada Act
- Guidance Document - Supporting Evidence for Implantable Medical Devices Manufactured by 3D Printing
- Notice: Therapeutic Products with Paediatric Labelling
- Official Method: Conjugated Estrogens
- Official Method: Determination of Flame Projection
- Official Method: Determination of Net Contents
- Official Method: Determination of the Disintegration Time of Tablets
- Official Method: Thyroid
- Opioid Medicines – Part A: Opioid Warning Sticker
- Opioid Medicines – Part B: Opioid Patient Information Handout
- Opioid Pain Medications
- Opioid Warning Sticker and Patient Information Handout, and Risk Management Plans
- Opioid Pain Medications Frequently Asked Questions
- Pause-the-Clock Proposal for Drug and Medical Device Establishment Licence Applications
- Performance Standards for the Fees in Respect of Drugs and Medical Devices Order
- Post-Drug Identification Number (DIN) Changes Guidance Document
- Protecting Canadians from Excessive Drug Prices: Consulting on Proposed Amendments to the Patented Medicines Regulations
- Questions and Answers - Access to Drugs in Exceptional Circumstances
- Questions and Answers - Guidance Document Non-Clinical Laboratory Study Data Supporting Drug Product Applications and Submissions: Adherence to Good Laboratory Practice
- Questions and Answers Document - Structure and Content of Clinical Study Reports - ICH Topic E3(R1)
- Questions and Answers Document: Ethnic Factors in the Acceptability of foreign Clinical Data - ICH Topic E5(R1)
- Questions and Answers Regarding the Adoption of Periodic Benefit Risk Evaluation Report (PBRER) Review at Health Canada
- Questions and Answers: Prescription Opioids – Sticker and Handout Requirements for Pharmacists and Practitioners
- Registration and Disclosure of Clinical Trial Information
- Regulatory Decision Summaries
- Regulatory enrolment process (REP)
- Risk of thermal harm from therapeutic and cosmetic energy-based medical devices: Notice to industry
- Special Access Program for drugs: Guidance document for industry and practitioners
- Special Access Programme - Drugs